Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-28T08:10:21.457Z Has data issue: false hasContentIssue false
  • English
  • Français

Current approaches to the management of schizophrenia

Published online by Cambridge University Press:  13 June 2014

Caragh Behan
Caragh Behan*
Affiliation:
Cluain Mhuire family Services, Newtownpark Avenue, Dublin
*
*Correspondence E-mail: caragh.behan@sjog ie
Get access Rights & Permissions [Opens in a new window]

Extract

Welcome to the second module in our Continuing Professional Development Section (CPD). CPD is now a key element in the clinical activity of all health professionals and a cornerstone of good clinical governance throughout mental health services. This section of the Irish Journal of Psychological Medicine will provide CPD modules dedicated to key topics in mental health care. In order to assist learning and self-assessment, multiple choice questions will be provided at the end of each module.

This module and its multiple choice questions are available online on the website of the Irish Journal of Psychological Medicine (www.ijpm.org). The CPD policy of the College of Psychiatry of Ireland indicates that psychiatrists who participate in suitable online learning which fits the criteria for CPD may claim CPD points under the Personal CPD category (up to a maximum of 5 points per year).

We are confident that this CPD Section of the Irish Journal of Psychological Medicine will prove to be a valuable resource for consultant psychiatrists, psychiatric trainees and all journal readers. We welcome feedback from readers and, especially, any suggestions for topics to be covered in future CPD modules. Suggestions should be emailed to: [email protected]

Type
Continuing Professional Development – New!
Information
Irish Journal of Psychological Medicine , Volume 26 , Issue 3 , September 2009 , pp. i - vii
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Sana, S. Chant, D, Welham, J, McGrath, J. A Systematic review of the prevalence of Schizophrenia. PLoS Medicine Vol 2, No. 5, e141 DOI: 10.1371/journal.pmed.0020141Google Scholar
2.Jablensky, A. Sartorius, N, Ernberg, G, Anker, M, Korten, A, Cooper, JEet al.Schizophrenia: manifestations, incidence and course in different cultures. A Worl d Health Organization ten-country study. Psychol Med Monogr Suppl 1992; 20: 1–97CrossRefGoogle Scholar
3.Rosenheck, RA, Leslie, DL, Sindelar, J, Miller, EA, Lin, H. Stroup, TSet al.Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry, 2006; 163: 2080–2089CrossRefGoogle Scholar
4.Lieberman, JA, Stroup, S, McEvoy, J, Swartz, M. Rosenheck, R, Perkins, D, et alfor the CATIE Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. N Engl J Med 2005; 353:1209–1223CrossRefGoogle Scholar
5.Oosthuizen, P, Emsley, RA, Turner, J, Keyter, N. Determining the optimal dose of haloperidol in first episode psychosis. J psychopharmacol 2001; 15: 251–255CrossRefGoogle ScholarPubMed
6.Taylor, D, Paton, C, Kerwin, R. The South London and Maudsley NHS Foundation Trust and Oxleas NHS Foundation Trust Prescribing Guidelines: 9th Ed. Published by Informa Health Care: London 2007Google Scholar
7.Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update) National clinical practice guideline Number 82. March 2009. National Collaborating Centre for Mental Health. Commissioned by the NICE.Google Scholar
8.Jones, PB, Barnes, TRE, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KPet al.Randomized controlled trial of the effect on quality of life of second-vs-first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63 1079–1087CrossRefGoogle Scholar
9.Lewis, SW, Davies, LM, Jones, P, Barnes, T. Murray, R, Kerwin, R. Randomized controlled trials of conventional antipsychotic versus new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technology Assessment 2006; 10, 1–165CrossRefGoogle ScholarPubMed
10.Lewis, SW, Barnes, TRE, Davies, L, Murray, RM, Dunn, G, Hayhurst, KPet al.Randomized controlled trial of effect of prescription of clozapine versus other second generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32: 715–723CrossRefGoogle ScholarPubMed
11.Brenner, HD, Dencker, SJ, Goldstein, MJ, Hubbard, JW, Keegan, DL, Kruger, Get al.Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990; 16:551–561CrossRefGoogle ScholarPubMed
12.Lieberman, JA, Alvir, JM. Woerner, M, Degreef, G, Bilder, RM, Ashtari, Met al.Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophr Bull 1992; 18: 351–371CrossRefGoogle ScholarPubMed
13.Conley, RR, Buchanan, RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997; 23; 663–674CrossRefGoogle ScholarPubMed
14.Chakos, M, Lieberman, J, Hoffman, E, Bradford, D, Sheitman, D. Effectiveness of secondgeneration antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518–526CrossRefGoogle ScholarPubMed
15.Wahlbeck, K, Cheine, MV, Essali, A. Clozapine versus typical neuroleptic medication for schizophrenia (Cochrane review). Cochrane Library, Issue 3. 1999; Oxford: Update SoftwareGoogle Scholar
16.Iqbal, MM, Rahman, A, Husain, Z. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003; 15: 33–48CrossRefGoogle ScholarPubMed
17.Cipriani, A, Boso, M, Barbui, C. Clozapine combined with different antipsychotic drugs for the treatment resistant schizophrenia. Cochrane Database Syst Rev 2009; 3:CD006324Google Scholar
18.Walker, AM, Lanza, LL, Arellano, F, Rothman, KJ. Mortality in current and former users of clozapine. Epidemiology 1997; 8(6): 671–7CrossRefGoogle ScholarPubMed
19.Munro, J, O'Sullivan, D, Andrews, C, Arana, A, Mortimer, A, Kerwin, R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999; 175:576–80CrossRefGoogle Scholar
20.Meltzer, HY, Alphs, I, Green, Al, Altamure, AC, Anand, R, Bertoldi, Aet alClozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60(1): 82–9CrossRefGoogle ScholarPubMed
21.Tiihonen, J, Lönnqvist, J, Wahlbeck, K, Klaukka, T, Niskanen, L, Tanskanen, A. Haukka, J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009 July (Epub ahead of print) PMID: 19595447Google Scholar
22. Consensus statement on high-dose antipsychotic medication CR 138 Royal College of Psychiatrists, London 2006 http://www.rcpsych.ac.uk/publications/collegereports/cr/cr138.aspxGoogle Scholar
23.Correll, CU, Rummel-Kluge, C, Kane, JM, Leucht, S. Antipsychotic combination vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35(2):443–457CrossRefGoogle ScholarPubMed
24.Cascade, EF, Kalali, AH, Buckley, PF. Current management of schizophrenia: Antipsychotic monotherapy versus combination therapy. Psychiatry 2008; 5 (28-29): 1550–5952Google ScholarPubMed
25.Goodwin, G, Fleischhacker, W, Arango, C, Baumann, P, Davidson, M, de Hert, Met al.Advantages and disadvantages of combination treatment with antipsychotics: ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009; 19 (7): 520–32. Epub 2009CrossRefGoogle ScholarPubMed
26.Krebs, M, Leopold, K, Hinzpeter, A, Schaefer, M. Neuroprotective agents in schizophrenia and affective disorders. Expert Opin Pharmacother 2006; 7(7): 837–848 DOI 0.1517/14656566.7.7.837CrossRefGoogle ScholarPubMed
27.Irving, CB, Mumby-Croft, R, Joy, LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database of Systematic Reviews 2009; (1): CD001257. DOI: 10.1002/14651858.CD001257.pub2Google Scholar
28.Rummel-Kluge, C, Kissling, W, Leucht, S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database of Systematic Reviews 2006; (3): CD005561. DOI:10.1002/14651858.CD005581.pub2Google Scholar
29.Hennekens, CH, Hennekens, AR, Hollar, D, Casey, DE. Schizophrenia and increased risks of cardiovascular disease. Am heart J 2005; 150: 1115–21CrossRefGoogle ScholarPubMed
30.American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psychiatry 2004; 65: 267–272CrossRefGoogle Scholar
31.Mackm, P, Bishop, D, Watkinson, HMetabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 2007; 191: 23–29CrossRefGoogle Scholar
32.International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdfGoogle Scholar
33. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update) National clinical practice guideline Number 82. March 2009. National Collaborating Centre for Mental Health. Commissioned by NICEGoogle Scholar
34.A Vision for Change. Report of the Expert Group on Mental Health Policy. Department of Health and Children (Ireland). Dublin: The Stationary Office 2006Google Scholar
35.Thakore, JH. Metabolic syndrome and schizophrenia. Br J Psychiatry 2005; 186: 455–456CrossRefGoogle ScholarPubMed
36.Pompili, M, Amador, XF, Girardi, P, Harkavy-Friedman, J, Harrow, M, Kaplan, Ket al.Suicide risk in schizophrenia: learning from the past to change the future. Annals of General Psychiatry 2007; 6:10 doi:10.1186/1744-859X-6-10CrossRefGoogle ScholarPubMed
37.Expert Consensus Meeting 2005 Metabolic and lifestyle issues and severe mental illness new connections to well-being? J Psychopharmacol 2005; 19 (6) suppl: 118–122 DOI:10.1177/0269881105058986Google Scholar
38.Wykes, T, Steel, C, Everitt, B, Tarrier, N. Schizophr Bull 2008; 34(3):523–537CrossRefGoogle Scholar
39.Kuller, AM, Ott, BD, Goisman, RM, Wainwright, LD, Rabin, RJ. Cognitive Behavioural Therapy and Schizophrenia: A Survey of Clinical Practices and Views on Efficacy in the United States and United Kingdom. Community Ment Health J 2009; Jul 25 (Epub ahead of print) PMID: 19633957Google Scholar
40.Goldberg, E, Gold, JM. Neurocognitive functioning in patients with schizophrenia: an overview. In: Bloom, FE, Kufler, DJ eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1995; 1171–1183Google Scholar
41.Russell, AJ, Monro, JC, Jones, PB, Hemsly, DR, Murray, RM. Schizophrenia and the myth of intellectual decline. Am J Psychiatry 1997; 154: 635–639Google ScholarPubMed
42.Meuser, KT: Cognitive functioning, social adjustment and long-term outcome in schizophrenia, in Cognition in Schizophrenia: Impairments, Importance and Treatment Strategies. Ed Sharma, T, Harvey, P. Oxoford, Uk, Oxford University Press, 2000, p157–177Google Scholar
43.Wexler, BE, Bell, MD. Cognitive remediation and vocational rehabilitation for schizophrenia. Schizophr Bull 2005; 31: 931–941CrossRefGoogle ScholarPubMed
44.Mogami, T. Cognitive Remediation for Schizophrenia. Yonago Acta Med 2007; 50: 69–80Google Scholar
45.McGurk, SR, Mueser, KY, Feldman, K, Wolfe, R, Pascaris, A. Cognitive training for supported employment: 2-3 year outcomes of a randomized controlled trial. Am J Psychiatry 2007; 164: 437–441CrossRefGoogle ScholarPubMed
46.Nose, M, Barbui, C, Tansella, M. How often do patients with psychosis fail to adhere to treatment programme? A systematic review. Psychol Med 2003; 33(7): 1149–1160CrossRefGoogle ScholarPubMed
47.Robinson, DG, Woerner, MG, Alvir, JMJ, Bilder, R, Goldman, R, Geisler, S. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241–247CrossRefGoogle ScholarPubMed
48.Kemp, R, Hayward, P, Applewhaite, G, Everitt, B, David, A. Compliance therapy in psychotic patients: a randomised controlled trial. Br Med J 1996; 312: 345–349CrossRefGoogle ScholarPubMed
49.Pekkala, E, Merinder, L. Psychoeducation for schizophrenia. Cochrane Database Syst Rev Update in: Cochrane Database Syst Rev. 2002; 2:CD002831 PMID: 11034771Google Scholar
50.Lanzara, D, Cosentino, U, LoMaglio, AM, Lora, A, Nicolo, A, Rossini, MS. Problems of patients with schizophrenic disorders and of their families. Epidemiol Psychiatr Soc 1999; 2: 117–30CrossRefGoogle Scholar
51.Mcfarlane, WR, Dixon, L, Lukens, E, Lucksted, A. Family psychoeducation and schizophrenia: a review of the literature. J Marital Fam Ther 2003; 29(2):223–45CrossRefGoogle ScholarPubMed
52.Tarrier, N, Lewis, S, Haddock, G, Bentall, R, Drake, R, Kinderman, Pet al.Cognitive behavioural therapy in first-episode and early schizophrenia. 18-month follow-up randomised controlled trial. Br J Psych 2004; 184:231–9CrossRefGoogle ScholarPubMed
53.Kern, RS, Glynn, SM, Horan, WP, Marder, SR. Psychosocial Treatments to Promote Functional Recovery in Schizophrenia. Schizophr Bull 2009; 35: 347–361CrossRefGoogle ScholarPubMed
54.Kurtz, MM, Meuser, KT. A meta-analysis of controlled research on social skills training in schizophrenia. J Consult Clin Psychol 2008; 76: 491–504CrossRefGoogle ScholarPubMed
55.Crowther, RE, Marshall, M, Bond, GR and Huxley, P. Vocational rehabilitation for people with severe mental illness. Cochrane database of Systematic Reviews 2001 Issue 2 Art: CD003080 DOI: 10.1002/14651858.CD003080CrossRefGoogle Scholar
56.Bond, GR, Boyer, SL. Rehabilitation programs and outcomes. Eds. Ciardiello, JA, Bell, MD. In: Vocational Rehabilitation of Persons With Prolonged Mental Illness. Baltimore, MD: Johns Hopkins University Press, 1988. pp. 231–263Google Scholar
57.Lehman, AF. Vocational Rehabilitation in Schizophrenia. Schizophrenia Bulletin 1995; 21 (4): 645–656CrossRefGoogle ScholarPubMed
58.Addmgton, J. The prodromal stage of psychotic illness: Observation, detection or Intervention? J Psychiatry Neurosci 2003; 28 (2): 93–97Google Scholar
59.Cannon, TD, Cadenhead, K, Cornblatt, B, Woods, SW, Addington, J, Walker, Eet al.Prediction of psychosis in youth at high clinical risk: a multi-site longitudinal study in North America. Arch Gen Psychiatry 2008; 65(1): 28–37CrossRefGoogle Scholar
60.Ruhrmann, S, Schultze-Lutter, F, Maier, W, Klosterkötter, J. Pharmacological intervention in the initial prodromal phase of psychosis. Eur Psychiatry 2005; 20(1): 1–6CrossRefGoogle ScholarPubMed
61.Cornblatt, BA, Lencz, T, Smith, CW, Olsen, R, Auther, AM, Nakayama, Eet al.Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 2007; 68(4): 546–57CrossRefGoogle ScholarPubMed
62.Fusar-Poli, P. Valmaggia, L, McGuire, P. Can antidepressants prevent psychosis? Lancet 2007; 370(9601): 1746–8CrossRefGoogle ScholarPubMed
63.McGorry, PD, Yung, AR, Phillips, LJ, Yuen, HP, Francey, S, Cosgrave, EMet al.Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59(10): 921–8CrossRefGoogle Scholar
64.McGlashan, TH, Zipursky, RB, Perkins, D, Addington, J, Miller, T, Woods, SWet al.Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163(5): 790–9CrossRefGoogle ScholarPubMed
65.Norman, RM, Malla, AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med 2001; (3): 381–400CrossRefGoogle ScholarPubMed
66.Clarke, M, Whitty, P, Browne, S, McTigue, O, Kamali, M, Gervin, Met al.Untreated illness and outcome of psychosis. Br J Psychiatry 2006; 189: 235–40CrossRefGoogle ScholarPubMed
67.Clarke, M, Whitty, P, Browne, S, Mc Tigue, O, Kinsella, A, Waddmgton, JLet al.Suicidally in firstepisode psychosis. Schizophr Res 2006; 86(1-3): 221–5CrossRefGoogle Scholar
68.Kapur, S, Remington, G, Jones, C, Wilson, A, DaSilva, J, Houle, Set al.High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996; 153:948–950Google ScholarPubMed
69.Cookson, J, Taylor, D, Katona, C. Use of Drugs in Psychiatry (5th edn). 2002. London: Published by Gaskell.Google Scholar
70.McEvoy, JP, Schooler, NR, Wilson, WH. Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacol Bull 1991; 27: 97–101Google ScholarPubMed
71.Tauscher, J, Kapur, S. Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs 2001; 15: 671–678CrossRefGoogle ScholarPubMed
72.Lehman, AF, Steinwachs, DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24(1): 1–10CrossRefGoogle ScholarPubMed
73.Möller, HJ & van Zerssen, D. Course and outcomes of schizophrenia. In: Schizophrenia, editors Hirsch, SR, Weinberger, DR. 1995. p106–127Oxford: Published by Blackwell.Google ScholarPubMed
74.Robinson, DG, Woerner, MG, Alvir, JM, Geisler, S, Koreen, A, Sheitman, Bet al.Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156(4): 544–9CrossRefGoogle ScholarPubMed
75.Haro, JM, Suarez, D, Novick, D, Brown, J, Usall, J, Naber, D; SOHO Study Group.. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007; 17(4): 235–44CrossRefGoogle ScholarPubMed
76.Gaebel, W & Frommann, N. Long-term course in schizophrenia: concepts, methods and research strategies. Acta Psychiatr Scand 2000; 102, 49–53CrossRefGoogle Scholar
77.Harrison, G, Hopper, K, Craig, T, Laska, E, Siegel, C, Wanderling, Jet al.Recovery from psychotic illness: a 15-an d 25-year international follow-up study. Br J Psychiatry 2001; 178:506–17CrossRefGoogle Scholar
78.Jobe, TH, Harrow, M. Long-term outcome of patients with schizophrenia: a review. Can J Psychiatry. 2005; 50(14): 892–900CrossRefGoogle ScholarPubMed
79.De Haan, L, Linszen, DH, Lenior, ME, de Win, ED, Gorsira, R. Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication. Schizophr Bull 2003; 29(2): 341–8CrossRefGoogle ScholarPubMed